TY  - JOUR
AU  - Haussmann, Robert
AU  - Homeyer, P.
AU  - Brandt, Daniel Moritz
AU  - Donix, M.
TI  - Prognostischer und differenzialdiagnostischer Stellenwert der Liquordiagnostik bei neurodegenerativen Demenzerkrankungen.
JO  - Der Nervenarzt
VL  - 93
IS  - 12
SN  - 0028-2804
CY  - Heidelberg
PB  - Springer
M1  - DZNE-2022-01173
SP  - 1236-1242
PY  - 2022
AB  - Cerebrospinal fluid (CSF) analysis is an important diagnostic tool in the assessment of dementia. For the differentiation of Alzheimer's disease from other etiologies of dementia syndromes, established biological markers could be helpful to confirm a distinctive neuropathology. Whereas negative CSF findings can rule out the majority of primarily neurodegenerative disorders, overlapping biomarker profiles remain a diagnostic challenge. Therefore, it is important to interpret CSF results within a specific clinical context. Furthermore, atypical CSF data can be challenging and require profound knowledge of preanalytics, biomarker profiles and the broad spectrum of diseases associated with cognitive decline. Beyond the Alzheimer's disease clinical spectrum, current studies aim at investigating CSF biomarkers to better differentiate tauopathies, TDP43(Transactive response DNA binding protein 43 kDa)-proteinopathies and synucleinopathies.
KW  - Humans
KW  - Alzheimer Disease: diagnosis
KW  - tau Proteins: cerebrospinal fluid
KW  - Prognosis
KW  - Neurodegenerative Diseases: diagnosis
KW  - Biomarkers: cerebrospinal fluid
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Alzheimer’s disease (Other)
KW  - Cerebrospinal fluid analysis (Other)
KW  - Frontotemporal dementia (Other)
KW  - Lewy body dementia (Other)
KW  - Neurodegenerative disease (Other)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC9718879
C6  - pmid:35670835
DO  - DOI:10.1007/s00115-022-01339-6
UR  - https://pub.dzne.de/record/164643
ER  -